ClinicalTrials.gg

Program

PF-07976016

A development code. Also written as “PF-07976016 Formulation A” and “PF-07976016 Formulation B”.

Its studies are mostly in Obesity, led by Pfizer.

Furthest: phase 2, since Dec 2, 20244 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer40 open or runningphase 2since Dec 2, 2024Oct 31, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 31, 2024First study: phase 1 study in Healthy VolunteersFirst studyNCT06670170 · 12 enrolled · United States
  2. Dec 2, 2024Phase 2 study in ObesityNCT06717425 · 263 enrolled · United States, Canada, Poland
  3. Mar 12, 2025Phase 1 study in OverweightNCT06910839 · 21 enrolled · United States
  4. Jun 3, 2025Phase 1 study in Healthy Male VolunteersNCT07015918 · 8 enrolled · Netherlands

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07015918Healthy Male Volunteers · Netherlands1CompletedJul 16, 20258
NCT06910839Overweight · United States1TerminatedMay 1, 202521
NCT06717425Obesity · United States, Canada, Poland2CompletedOct 23, 2025263
NCT06670170Healthy Volunteers · United States1CompletedDec 24, 202412

How it is read

Names in the registry

  • “PF-07976016”, 3 entries
  • “PF-07976016 Formulation A”, 1 entry
  • “PF-07976016 Formulation B”, 1 entry

Codes read as this program: PF07976016.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
PF-07976016 (Pfizer): development program | ClinicalTrials.gg